Welcome
Support Centre
14 March 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN78953383
Date ISRCTN assigned01/07/2001
Local reference number(s)G31
Public titleRandomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
Scientific title
AcronymN/A
Disease/condition/study domainOvarian Cancer
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewEthics information not required at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Confirmed diagnosis of invasive epithelial ovarian carcinoma including the following histological subtypes: Serous cystadenocarcinoma; Mucinous cystadenocarcinoma; Endometriod carcinoma; Clear cell (mesonephroid) carcinoma; Undifferentiated carcinoma
2. International Federation of Gynecology and Obstetrics (FIGO) stage Ic, II, III and IV
3. Age 18 -70 years
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
5. Life expectancy of at least 3 months
6. Adequate bone marrow and renal function
7. No previous chemotherapy or radiotherapy
8. No history of previous malignancy, except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
9. No serious intercurrent disease
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/01/1991
Anticipated end date01/03/1991
Status of trialCompleted
Target number of participantsNot provided at time of registration
Interventions1. Group A: Cisplatin 50 mg/m2 plus 750 mg/m2 cyclophosphamide repeated every 3 weeks for a maximum of six cycles
2. Group B: Cisplatin 100 mg/m2 plus 750 mg/m2 cyclophosphamide repeated every 3 weeks for a maximum of six cycles
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingCancer Research UK
Sponsor nameCancer Research UK
Sponsor detailsPO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
Sponsor telephone+44 (0)20 7317 5186
Sponsor fax+44 (0)20 7487 4302
Sponsor emailkate.law@cancer.org.uk
Sponsor websitehttp://www.cancer.org.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN78953383
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
terms & conditions | privacy statement | © Current Controlled Trials Ltd. Part of Springer Science+Business Media.


BioMed Central